Registry for tracking acute heart attacks
Registry of Acute Myocardial Infarction
This study is tracking heart attacks in Tomsk, Russia, to see how many people are affected and how they are doing over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 97500 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences Academic / other |
| Locations | 1 site (Tomsk) |
| Trial ID | NCT06252168 on ClinicalTrials.gov |
What this trial studies
The Registry of Acute Myocardial Infarction (RAMI) collects and processes standardized information on confirmed and suspected cases of acute myocardial infarction (AMI) using WHO-recommended diagnostic criteria. Data is gathered from all medical institutions in Tomsk, Russia, and recorded in a specialized database designed for statistical analysis and reporting. Each case is categorized based on diagnostic criteria after 28 days from the onset of symptoms, allowing for comprehensive epidemiological analysis of AMI in the population. The study aims to monitor morbidity, mortality, and lethality associated with AMI.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 20 and older who are residents or visitors of Tomsk and have experienced definite or possible acute myocardial infarction.
Not a fit: Patients who do not meet the age requirement or are not located in Tomsk at the time of AMI onset may not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could improve the understanding and management of acute myocardial infarction, leading to better patient outcomes.
How similar studies have performed: Other studies utilizing similar registry approaches have shown success in improving patient outcomes and understanding disease epidemiology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age of at least 20 years; * being a resident or visitor of the city of Tomsk at a time of AMI onset; * the presence of definite AMI or possible AMI. Definite AMI is diagnosed in the presence of characteristic ECG changes, regardless of clinical course and changes in serum enzymes; or the presence of typical pain syndrome, "ambiguous" ECG changes, and definite increase in the activity of serum enzymes i.e. exceeding the upper limit of normal by 25% or more; or macroscopically detected focus of myocardial necrosis and (or) fresh thrombotic occlusion of the coronary artery. Possible AMI is registered in the presence of typical pain syndrome with ambiguous ECG changes and an ambiguous (up to 25%) increase in the levels of serum enzymes; or the presence of obstruction in the lumen of at least one coronary artery by at least 50% and (or) the presence of a post-infarction scar in the myocardium with a diameter of 0.5 cm or more, while simultaneously excluding a non-coronary cause of death. In case of atypical clinical picture, ambiguous or absent ECG changes, when the enzyme levels are not determined or their activity does not reach a pathological level, AMI case is considered unconfirmed. In the absence of data that could confirm or not confirm AMI, the case is interpreted as "insufficient data" Exclusion Criteria: * none.
Where this trial is running
Tomsk
- Tomsk National Research Medical Center, Russian Academy of Sciences — Tomsk, Russia (Recruiting)
Study contacts
- Principal investigator: Sergey A. Okrugin, MD, PhD — Tomsk NRMC
- Study coordinator: Sergey A. Okrugin, MD, PhD
- Email: sao@cardio-tomsk.ru
- Phone: +73822554111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.